To determine:
1. Stimulants (methylphenidate, dextroamphetamine or pemoline) vs. stimulants (trials comparing the same drug were included if different formulations of different enantiomers).
Stimulants vs. tricyclic antidepressants.
3. Stimulants vs. clonidine, buproprion, or selective serotonin-reuptake inhibitors were eligible for inclusion.
Tricyclic Antidepressants vs. Placebo: Studies that compared placebo with amitriptyline, imipramine, or desipramine.
Drug vs. Nondrug Studies: studies in which:
1. One of the study arms included only a stimulant drug.
2. One or more of the control arms included other modes of intervention such as behaviour modification, dietary interventions, or other psychosocial interventions.
Combination Therapy: studies in which:
1. One of the study arms included two or more interventions given in combination.
2. One of the study arms included a stimulant. Long-Term Therapy: studies that evaluated treatment for 12 weeks or more in all study arms. Specific interventions included: amphetamine, attention control/child training, behaviour modification, bibliotherapy protocol, buproprion, caffeine, child training, chlorpromazine, clonidine, cognitive behavioural therapy, desipramine, dexamphetamine, EEG biofeedback, efamol, haloperidol, hydroxyzine, imipramine, L-amphetamine, lithium carbonate, lethylphenidate, nicotine, nothing (e.g. waiting lists), parent training, pemoline, phenylalanine, pinodol, placebo, racemic amphetamine, secobarbitol, selegiline, supportive therapy and thiordazine.
Participants included in the review
Both adults and children suffering from ADHD. For treatment of ADHD in adults, a study was included if treatments were evaluated in patients older than 18 years of age. Studies that included conditions other than ADHD were included only if they provided separate analyses for patients with ADHD.
Outcomes assessed in the review
Outcomes of interest extracted were: abdominal pain; achievement tests; aggressiveness; anorexia; anxiety; arithmetic; behaviour disturbances; CD; core symptoms; crying; decreased appetite; depression; disturbed sleep; emotional; fatigue/tiredness; global mood; global side effects; global symptoms; grades; growth; headache; height; hyperactivity; impulsivity; inattention; increased appetite; interaction with family; interaction with friends; irritability; listening; motor tics; nausea; nightmares; ODD; reading; performance; sadness; self-control; self-esteem; sleep disorder -insomnia; sleep disorder -sleep; social competence; somatic effects; spelling; verbal; weight; weight gain; and weight loss.
The following tests were used: ACTeRS; ADHD rating scale; Beck Depression Inventory; Behaviour Problem Checklist; Brief Psychiatric Rating Scale; CGI -Global Improvement; CGI -Severity of Illness; Child Psychological Rating; Children's Checking Task; Children's Depression Inventory; Clinical Global Improvement; Conners Child/Self; Conners Parent Rating Scale; Conners Teacher/Spouse; CPT; DETROIT13; DETROIT16; DETROIT6; DTS; Durrell Anal. Reading; EFT; Gates McGinty Test; Global Assessment Scale; HAM-A; Hamilton Psychiatric RatingDepression; How I Feel; Humphries Self-control -Teacher; KBIT; MFFT; Other Clinician Report; Other Parent report; Other Teacher Report; Peterson Quay Checklist; PGS; Physician Global Assessment of Change; Piers Harris Scale; POMS; PTSR; Report Only; SNAP; STESS; STM Task; Unspecified reaction performance; Werry Weiss Activity Scale; Weschler; and WRAT.
How were decisions on the relevance of primary studies made?
Hard copies of studies were obtained and independently assessed by two members of the research team who then decided, by consensus, whether to include the study.
Assessment of study quality
The quality of each study was assessed using a Quality Assessment Scale (see Other Publications of Related Interest no.2). Studies were given a score of 1 point for each of the criteria they satisfied. The scoring range was 0-5, a score of less than 3 was deemed to be poor quality. Two reviewers performed the quality assessment and disagreements were resolved by consensus and by referring to the information in the original report.
Data extraction
Data extraction forms were specially developed and tested. Two reviewers extracted data independently from each of the full reports. Any differences were resolved by consensus and by referring to the information in the original report. Any differences that could not be resolved by the two reviewers who extracted the data were resolved by the task order leader or by a member of the local research team. The original reports were not masked. The information extracted addressed 41 different aspects of the studies which were selected by the team members a priori. Aspects assessed included: evidence of bias, patient characteristics, links to pharmaceutical or related industry, sampling issues, diagnosisrelated issues, and treatment-related issues.
Methods of synthesis
How were the studies combined?the studies (e.g. therapies evaluated, patient populations, duration), inconsistency in outcome measurements, low methodological quality, and incomplete data reporting. Study results were grouped into seven categories.
How were differences between studies investigated?
The authors do not describe a formal method for assessing heterogeneity but state that 'substantial clinical heterogeneity' was found.
Results of the review
One hundred and thirty-five RCTs and 1 non-RCT.
The average quality score was 2 out of 5 points. Only one study was given the maximum quality score of 5 points.
Drug vs. Drug comparisons (n = 22 RCTs): few, if any, differences among methylphenidate (MPH) and dextroamphetamine (DEX), and pemoline; studies comparing stimulants with tricyclic antidepressants were inconclusive.
Drug vs. non-drug studies (n = 6 RCTs): stimulants, particularly MPH, may be more effective than nonpharmacological interventions.
Combination therapy (n = 20 RCTs): no additional beneficial effects for combination therapies were shown.
Tricyclic antidepressants vs. placebo (n = 9 RCTs): desipramine may be more effective than placebo; no consistent effect was shown for imipramine.
Long term therapy (>=12 weeks) (n = 14 RCTs (13 in school children and 1 in adults)): a trend to general improvement regardless of treatment was found, but the length of follow-up was inadequate. MPH may reduce behavioural disturbance in children with ADHD while it is taken. Academic performance does not appear to be improved with stimulants.
Treatment of ADHD in adults (n = 12 RCTs): for MPH vs. placebo, the results were contradictory. Antidepressants may be effective in adults, but no beneficial effect was seen with pemoline, nicotine, or phenylalanine compared with placebo.
Adverse effects of drug therapy (n = 28 RCTs, 1 non-RCT): many of the side effects associated with stimulant use appear to be relatively mild and of short duration and to respond to dosing or timing adjustments. Data are inadequate on the long-term effects and severity of adverse effects of most interventions. No comparative studies were identified with data on important adverse effects of interest, including potential for abuse of stimulants, liver toxicity due to pemoline, or major arrhythmia with tricyclic antidepressants.
